医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

製薬

PerkinElmer’s Horizon Discovery CHOSOURCE Cell Line Supports Trinomab Biotech’s Development of the World-First, Tetanus Toxin mAb Drug for Clinical Trials

PerkinElmer’s Horizon Discovery CHOSOURCE Cell Line Supports Trinomab Biotech’s Development of the World-First, Tetanus Toxin mAb Drug for Clinical Trials

バイオテクノロジーヘルスケア医療機器臨床試験製薬　 TimeLine: mAb Drug for Clinical Trials PerkinElmer’s Horizon Discovery CHOSOURCE Cell Line Supports Trinomab Biotech’s Development of the World-First Tetanus Toxin

2021年02月05日

InnoCare Brings On Hillhouse as Strategic Investor, Vivo Capital Increases Holdings

InnoCare Brings On Hillhouse as Strategic Investor, Vivo Capital Increases Holdings

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: InnoCare Brings On Hillhouse as Strategic Investor Vivo Capital Increases Holdings

2021年02月04日

Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Forecast Raised for Free Cash Flow and Reported Full-Year Management Guidance for FY2020 Confirmed Results Demonstrate Growth Acceleration and Continued Resilience Takeda FY2020 Q

2021年02月04日

武田薬品工業: 2020年度第3四半期は成長の加速と引き続き底力を実証；通期のマネジメント・ガイダンスを維持し、フリー・キャッシュ・フローと財務ベースEPSの予想を上方修正

武田薬品工業: 2020年度第3四半期は成長の加速と引き続き底力を実証；通期のマネジメント・ガイダンスを維持し、フリー・キャッシュ・フローと財務ベースEPSの予想を上方修正

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: 上方修正実証底力武田薬品工業財務ベースEPS

2021年02月04日

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-192 in the U.S.

InnoCare Announces First Subject Dosed in Clinical Trial of ICP-192 in the U.S.

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: in the InnoCare Announces First Subject Dosed in Clinical Trial of ICP

2021年02月04日

emids Acquires Canadian Design-Led Software Engineering Firm Macadamian

emids Acquires Canadian Design-Led Software Engineering Firm Macadamian

バイオテクノロジーヘルスケア医療機器製薬　 TimeLine: emids Acquires Canadian Design-Led Software Engineering Firm Macadamian

2021年02月04日

Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China

Sinovac Files for Conditional Market Authorization of COVID-19 Vaccine in China

バイオテクノロジーヘルスケア感染症製薬　 TimeLine: Sinovac Files for Conditional Market Authorization of COVID Vaccine in China

2021年02月03日

Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx-99, an Experimental Treatment for Respiratory Viral Infection, Including COVID-19

Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx-99, an Experimental Treatment for Respiratory Viral Infection, Including COVID-19

バイオテクノロジーヘルスケアヘルス一般感染症臨床試験製薬　 TimeLine: Clinical Study of REVTx Completes Dosing Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase Including COVID Revelation Biosciences Inc

2021年02月03日

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLC

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: EGFR-Mutated NSCLC HERTHENA-Lung01 Phase Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with

2021年02月03日

Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活

バイオテクノロジーヘルスケア製薬　 TimeLine: Engrail Therapeutics收购NeuroCycle Therapeutics改进及优化药物以改善中枢神经系统疾病患者生活

2021年02月03日